144 related articles for article (PubMed ID: 32894834)
1. Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
Ambikaibalan D; Quaade AS; Halling AS; Thyssen JP; Egeberg A
Dermatology; 2021; 237(2):158-165. PubMed ID: 32894834
[TBL] [Abstract][Full Text] [Related]
2. Placebo response in phase 2 and 3 trials of systemic and biological therapies for atopic dermatitis-a systematic review and meta-analysis.
Andreasen TH; Christensen MO; Halling AS; Egeberg A; Thyssen JP
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1143-1150. PubMed ID: 31856331
[TBL] [Abstract][Full Text] [Related]
3. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
4. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
Papp KA; Yang M; Sundaram M; Jarvis J; Betts KA; Bao Y; Signorovitch JE
Value Health; 2018 Jan; 21(1):1-8. PubMed ID: 29304933
[TBL] [Abstract][Full Text] [Related]
6. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials.
Qiu Y; Zhu Y; Liu Y; Liu Q
J Dermatolog Treat; 2023 Dec; 34(1):2199106. PubMed ID: 37010492
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points.
Puig L; López A; Vilarrasa E; García I
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1633-53. PubMed ID: 24033851
[TBL] [Abstract][Full Text] [Related]
10. Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.
van Vugt LJ; van den Reek JMPA; Hannink G; Coenen MJH; de Jong EMGJ
JAMA Dermatol; 2019 Jun; 155(6):708-715. PubMed ID: 30994858
[TBL] [Abstract][Full Text] [Related]
11. Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules.
He H; Wu W; Zhang Y; Zhang M; Sun N; Zhao L; Wang X
Front Pharmacol; 2021; 12():586827. PubMed ID: 34276352
[No Abstract] [Full Text] [Related]
12. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
Zhang Z; Schmitt J; Wozel G; Kirch W
Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
Armstrong AW; Puig L; Joshi A; Skup M; Williams D; Li J; Betts KA; Augustin M
JAMA Dermatol; 2020 Mar; 156(3):258-269. PubMed ID: 32022825
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
Papp KA; Reich K; Blauvelt A; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaci D; Li Q; Cichanowitz N; Green S; La Rosa C
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
Schmitt J; Zhang Z; Wozel G; Meurer M; Kirch W
Br J Dermatol; 2008 Sep; 159(3):513-26. PubMed ID: 18627372
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.
Checchio T; Ahadieh S; Gupta P; Mandema J; Puig L; Wolk R; Valdez H; Tan H; Krishnaswami S; Tallman A; Kaur M; Ito K
Clin Pharmacol Ther; 2017 Dec; 102(6):1006-1016. PubMed ID: 28480503
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Kuo CM; Tung TH; Wang SH; Chi CC
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):355-362. PubMed ID: 29136293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
